The rapid lipopolysaccharide-induced release of matrix metalloproteinases 9 is suppressed by simvastatin

Dan-Dong Li1, Hong-Gang Pang1, Jin-Ning Song1

  • 1Department of Neurosurgery, the First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Insights

Statins, like simvastatin, significantly reduce matrix metalloproteinase-9 (MMP-9) release from stimulated leukocytes. This suppression occurs via the RhoA/ROCK pathway, not NF-κB or MAPKs.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Matrix metalloproteinase-9 (MMP-9) is upregulated in many diseases.
  • Statins may exert beneficial effects by suppressing MMP-9.

Purpose of the Study:

  • To investigate simvastatin's effect on MMP-9 and TIMP-1 in lipopolysaccharide (LPS)-stimulated rat leukocytes.
  • To elucidate the signaling pathways involved in MMP-9 regulation by statins.

Main Methods:

  • Leukocytes (neutrophils, monocytes) stimulated with LPS and simvastatin.
  • Assessed MMP-9 secretion (ELISA), mRNA (RT-PCR), and protein (Western blot).
  • Investigated signaling pathways using luciferase assays (NF-κB), pull-down assays (RhoA), and inhibitors.

Main Results:

  • LPS differentially induced MMP-9 and TIMP-1 in neutrophils and monocytes.
  • MMP-9 release primarily occurred via secretion from intracellular stores.
  • Simvastatin significantly suppressed LPS-induced MMP-9 release and mRNA expression in a time- and dose-dependent manner, delaying release by ~20 min.
  • Statin's suppressive effect on MMP-9 was mediated via the RhoA/ROCK pathway, independent of NF-κB and MAPKs.

Conclusions:

  • Simvastatin effectively suppresses LPS-induced MMP-9 release and expression in leukocytes.
  • The RhoA/ROCK pathway is the primary mediator of simvastatin's inhibitory effect on MMP-9, distinct from NF-κB and MAPK pathways.